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In this summary statement from the proceedings of the Consen-
sus Conference on Multidisciplinary Treatment of Hepatocellular
Carcinoma (HCC),1 the authors describe concisely and thor-
oughly the efficacy of multiple potentially curative treatment
options for HCC. Furthermore, the authors have emphasized
several areas of controversy in the field that remain open to
discussion.
The major question that this review addresses is ‘What is the
optimal treatment and/or sequence of treatments for patients
with early T stage disease?’ The data and references presented in
this manuscript highlight the fact that patients with early stage
HCC may be candidates for curative therapy with one of several
modalities including liver transplantation, liver resection, and
possibly radiofrequency ablation. No one modality fits all patient
scenarios; multidisciplinary teams of surgeons, oncologists,
hepatologists, and radiologists armed with a thorough under-
standing of the literature and these consensus guidelines are
best suited to assess each individual case and assign the optimal
treatment plan.
The discussion of these three modalities in particular should
always be made in the context of the epidemiology of the disease.
It is exceedingly rare for patients to present with HCC outside of
the setting of cirrhosis. Certainly, those patients who do present
with precirrhotic HCC are frequently candidates for liver resec-
tion based on their functional hepatic reserve. Although it is
common to see HCC patients with compensated cirrhosis
(Child-Turcotte-Pugh Class A and low Model for End Stage Liver
Disease (MELD) score), the majority of patients presenting with
HCC have more decompensated liver disease with portal hyper-
tension, eliminating resection and ablation from the treatment
armamentarium. At the same time, not all patients with ‘trans-
plantable’ stage HCC are eligible for liver transplantation, due to
medical, financial, or social concerns.2
In the setting of cirrhosis and HCC, the risks of resection and
radiofrequency ablation need to be carefully weighed against
that of transplantation. For United Network for Organ Sharing
(UNOS) T1 tumors (one lesion up to 2 cm) in patients with
pre-cirrhotic or well compensated cirrhosis with minimal portal
hypertension, there are likely equivalent patient survivals with
liver transplantation, surgical resection, and radiofrequency
ablation (RFA). As these patients are not advantaged on the liver
transplant waitlist and the availability of cadaveric allografts is
low for this patient group, it remains advisable that well com-
pensated cirrhotic patients with early T-stage disease pursue
non-transplant curative modalities.
In contrast, patients with UNOS T2 stage HCC (1 lesion less
than 5 cm or 2–3 lesions with none larger than 3 cm) are advan-
taged on the UNOS liver transplant list. Depending on UNOS
region and blood type, these patients may receive liver transplan-
tation with a short wait list time (less than six months of wait
time). Using current neoadjuvant treatment protocols (mainly
transarterial chemoembolization and/or RFA, but now also
systemic therapies) it is very rare to see a waitlist drop out from
progression of HCC in a patient with UNOS T2 disease and a
short wait time. Given these dynamics, this group of patients is
expected to receive a greater benefit from liver transplantation
than from other modalities.
These arguments emphasize that the decision on which curative
therapy is best suited for a given early T stage HCC patient
depends on four critical factors: the underlying liver function/
portal hypertension, the availability of/patient candidacy for
liver transplantation, the tolerance for early complications with
non-transplant modalities, and the focality of the tumor.
For example, a well compensated cirrhotic patient (minimal
portal hypertension and MELD < 10) with a small, solitary,
peripheral HCC lesion, evaluated in a competitive UNOS region
with a long anticipated wait time, should be considered for resec-
tion. In contrast, a MELD 18 cirrhotic patient with two HCC
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lesions, listed at a transplant center with a short anticipated
waitlist time is better approached with transplantation.
With regard to the specific comparison of outcomes between
liver transplant/resection and RFA, several important points
should be emphasized. Independent of HCC treatment modality,
the overwhelming majority of outcomes analyses indicate that
survival in patients with HCC is most closely associated with the
presence or absence of microvascular invasion.3–5 Both liver trans-
plantation and resection have the benefit of providing a pathology
specimen to obtain this critically important prognostic informa-
tion. In contrast, RFA and other destructive modalities remove
the possibility of obtaining this information for the clinician and
the patient. In addition, there is compelling evidence that local
recurrence after RFA in lesions larger than 2–3 cm is significant.6,7
Together, these data suggest that, in patients who are candidates
for extirpative modalities, resection and transplantation have
prognostic information advantages and a track record that
exceeds that of RFA.
Another area of controversy addressed in this summary is the
impact that down staging may have on patient eligibility for cura-
tive therapies in this disease. This discussion warrants several
comments. First, there is increasing evidence that response to
neoadjuvant therapy is a predictor of favorable HCC biology,
and therefore of success with subsequent curative treatments.8–10
Second, while the authors’ summary describes multiple novel
modalities and multimodality treatment strategies that may facili-
tate down staging of HCC, distinction should be made between
established modalities (thermal ablation, chemoembolization,
and ethanol injection) and unproven techniques (electroporation,
nanoparticles, systemic chemotherapy, and bland arterial embo-
lization). Third, the early data on equivalent outcomes achieved in
patients down staged from T3 to T2 and subsequently treated with
transplantation or resection are compelling, but needs further
study and validation.
Finally, this summary underscores the uncharted space open to
basic and clinical investigation in this field. Identification of an
ideal set of neoadjuvant therapies to use as ‘bridge therapies’
during wait times for liver transplantation or as down-staging
therapies for patients with advanced T-stage disease remains
elusive. In current practice, most patients who are eligible to
receive curative therapy for HCC are receiving more than one
form of therapy, be it local-regional and/or systemic. As we move
forward the most important challenge to be faced in effectively
treating this set of patients is identification of molecular profiles
that can predict the combination of therapies that will have the
most efficacy with the least amount of toxicity.
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